Aged mice were intraperitoneally injected with 5 mg/kg FOXO4-DRI or PBS as a control every other day for three administrations, and effects were assessed 30 days post-treatment
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, et al
Cell-penetrating peptides in diagnosis and treatment of human diseases: From preclinical research to clinical application
The usual dose is 1 mg per day, but this may be adjusted depending on the patient's individual needs
Phase 2 (weeks 9-16): Lean mass focus maintaining lower semaglutide dose, adding CJC-1295 + Ipamorelin for GH support, continuing BPC-157
Vialen's design ensures optimal storage and handling